<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00512681</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-07-264</org_study_id>
    <nct_id>NCT00512681</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer</brief_title>
  <acronym>TIROX2</acronym>
  <official_title>A Phase II Study of S-1 Combined With Irinotecan and Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be treated with irinotecan (150mg/m2) followed by oxaliplatin (85mg/m2)on day 1&#xD;
      and S-1(80mg/m2/day) from day 1 to 14 every 3 weeks. Patients will receive up to a planned&#xD;
      treatment of maximum 12 cycles of chemotherapy. Response assessement will be performed every&#xD;
      2 cycles of chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal overall response rate</measure>
    <time_frame>During chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival,Overall survival,Toxicity assessment,&amp;genetic polymorphism and association with chemical outcomes</measure>
    <time_frame>during study period</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Stomach Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan, Oxaliplatin, TS-1</intervention_name>
    <description>S-1 40 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)&#xD;
Irinotecan 150 mg/m2 mixed in d5w 500 ml iv over 90-min on days 1&#xD;
Oxaliplatin 85 mg/m2 mixed in d5w 250 ml iv over 2-h on days 1</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed gastric adenocarcinoma with recurrent or&#xD;
             metastatic disease&#xD;
&#xD;
          2. Age ≥18 years&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          4. Disease status must be that of measurable disease as defined by RECIST&#xD;
             criteria:Measurable lesions: Lesions that can be accurately measured in at least one&#xD;
             dimension by any of the following: - CT of abdomen, pelvis or thorax, if the longest&#xD;
             diameter to be recorded is at least 10 mm with spiral CT- Chest x-ray, if the lung&#xD;
             lesion to be recorded is clearly defined and surrounded by aerated lung and the&#xD;
             diameter to be recorded is at least 20 mm- Physical examination, if the clinically&#xD;
             detected lesions are superficial (e.g., skin nodule and palpable lymph nodes) and at&#xD;
             least 10 mm&#xD;
&#xD;
          5. No prior treatment for recurrent or metastatic disease; prior adjuvant/neoadjuvant&#xD;
             therapy is allowed if at least 12 months have elapsed between completion of&#xD;
             adjuvant/neoadjuvant therapy and enrolment into the study. However, prior oxaliplatin&#xD;
             and/or irinotecan as adjuvant therapy are not allowed.&#xD;
&#xD;
          6. Adequate major organ function including the following: Hematopoietic function: ANC ³&#xD;
             1,500/mm3, Platelet ³ 100,000/mm3Hepatic function: serum bilirubin 1.5 mg/dl, AST/ALT&#xD;
             levels 2.5 x UNL ( 5 x UNL if liver metastases are present)Renal function: serum&#xD;
             creatinine UNL&#xD;
&#xD;
          7. Patients should sign a written informed consent before study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior history of peripheral neuropathy&#xD;
&#xD;
          2. Inadequate cardiovascular function:New York Heart Association class III or IV heart&#xD;
             diseaseUnstable angina or myocardial infarction within the past 6 monthsHistory of&#xD;
             significant ventricular arrhythmia requiring medication with antiarrhythmics or&#xD;
             significant conduction system abnormality&#xD;
&#xD;
          3. Serious concurrent infection or nonmalignant illness that is uncontrolled or whose&#xD;
             control may be jeopardized by complications of study therapy&#xD;
&#xD;
          4. Other malignancy within the past 3 years except non-melanomatous skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          5. Psychiatric disorder that would preclude compliance&#xD;
&#xD;
          6. Pregnant, nursing women or patients with reproductive potential without contraception&#xD;
&#xD;
          7. Patients receiving a concomitant treatment with drugs interacting with S-1 such as&#xD;
             flucytosine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sook Ryun Park, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center Korea</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>August 7, 2007</study_first_submitted>
  <study_first_submitted_qc>August 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <last_update_submitted>September 17, 2009</last_update_submitted>
  <last_update_submitted_qc>September 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Sook Ryun Park, M.D</name_title>
    <organization>National Cancer Center, Korea</organization>
  </responsible_party>
  <keyword>Stomach Neoplasms</keyword>
  <keyword>Secondary</keyword>
  <keyword>Combination chemotherapy</keyword>
  <keyword>S-1</keyword>
  <keyword>irinotecan</keyword>
  <keyword>oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

